Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 7;2022(3):27.
doi: 10.5339/qmj.2022.27. eCollection 2022.

Ceftriaxone-induced hepatotoxicity in patients with common medical infections in Qatar: A retrospective study

Manish Barman  1   2 , Bassem Al Hariri  1 , Abdul Rahman Mustafa  1 , Naseem Ambra  1 , Israa Amjed  1 , Ahmad Eid Nazzal Alharafsheh  1 , M N Illahi  1   2 , S Hamuda  1 , Mohamedali Gaafar  1   2 , Muhammad Sharif  1   2
Affiliations

Ceftriaxone-induced hepatotoxicity in patients with common medical infections in Qatar: A retrospective study

Manish Barman et al. Qatar Med J. .

Abstract

Introduction: Ceftriaxone, a third-generation cephalosporin, is frequently used for the treatment of various bacterial infections as a broad-spectrum antibiotic for many decades. Although ceftriaxone is a well-tolerated drug in most cases, it can lead to serious liver injury, which can be a real challenge to the treating physician. Given the potentially serious adverse effects that can vary from mild biochemical abnormalities to complete liver failure, we intend to assess the spectrum of liver injury based on biochemical criteria for patients treated with ceftriaxone for common bacterial infections in Qatar.

Objectives: This study aimed to explore the incidence of ceftriaxone-induced liver injury at Hazm Mebaireek General Hospital, Qatar, and to evaluate the relationship of the ceftriaxone dose, if any, with liver dysfunction.

Methods: This retrospective study included hospitalized adult patients treated with ceftriaxone at our hospital from January 2019 to December 2019 and analyzed demographic and clinical data obtained from electronic medical records. This study determined the incidence of liver injury (primary outcome) in patients treated with ceftriaxone (2 g/day) for ≥ 2 consecutive days by reviewing liver function test results until the day of discharge and at the first outpatient follow-up.

Results: The final data analysis included a total of 634 patients admitted and treated with ceftriaxone from January 2019 to December 2019.In the multivariate analysis with propensity score adjustment, ceftriaxone was independently associated with liver injury, especially when combined with other agents utilizing hepatic metabolism.

Conclusions: Ceftriaxone was associated with a significantly higher incidence of liver injury (19.7%) when used along with other medications that are metabolized in the liver, as found in the present study compared with other similar studies (approximately 2.9%-13.9%). Furthermore, the incidence was too high to be ignored in clinical practice.

Keywords: Ceftriaxone; Drug-induced liver injury; drug-induced cholestasis; drug-induced hepatitis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow chart of patient selection
Figure 2.
Figure 2.
Bacterial culture growth isolates in the patient population.
See this image and copyright information in PMC

References

    1. Chitturi S, Farrell GC. Drug-induced cholestasis. Semin Gastrointest Dis 2001 Apr;12(2):113–24. PMID: 11352118. - PubMed
    1. Padda MS, Sanchez M, Akhtar AJ, Boyer JL. Drug-induced cholestasis. Hepatology 2011 Apr;53(4):1377–87. PMID: 21480339. - PMC - PubMed
    1. Sandrasegaran K, Alazmi WM, Tann M, Fogel EL, McHenry L, Lehman GA. Chemotherapy-induced sclerosing cholangitis. Clin Radiol 2006 Aug;61(8):670–8. PMID: 16843750. - PubMed
    1. Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010 Feb;51(2):615–20. PMID: 19839004. - PubMed
    1. Antoine DJ, Williams DP, Park BK. Understanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science. Expert Opin Drug Metab Toxicol 2008 Nov;4(11):1415–27. PMID: 18950283. - PubMed

LinkOut - more resources